HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner

Journal of Clinical Investigation

Volumn 111, Issue 10, 2003, Pages 1579-1587

  Gong, Ming ^a   Wilson, Melinda ^a   Kelly, Thomas ^a   Su, Wen ^a   Dressman, James ^a   Kincer, Jeanie ^a   Matveev, Sergey V ^a   Guo, Ling ^a   Guerin, Theresa ^a   Li, Xiang An ^a   Zhu, Weifei ^a   Uittenbogaard, Annette ^a   Smart, Eric J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN; NITRIC OXIDE; SCAVENGER; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; CD36 ANTIGEN; IMMUNOGLOBULIN RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPROTEIN RECEPTOR; MEMBRANE PROTEIN; NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN; NOS3 PROTEIN, MOUSE; SCARB1 PROTEIN, HUMAN; SCARB1 PROTEIN, MOUSE; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; UNITED STATES; VASODILATATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; FEMORAL ARTERY; GENETICS; HORMONE SUBSTITUTION; IN VITRO STUDY; METABOLISM; MOUSE MUTANT; OVARIECTOMY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD36; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; FEMORAL ARTERY; HORMONE REPLACEMENT THERAPY; HUMANS; LIPOPROTEINS, HDL; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OVARIECTOMY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOPROTEIN; RECEPTORS, SCAVENGER; SCAVENGER RECEPTORS, CLASS B; SEX FACTORS; VASODILATION;

EID: 85047693834     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI16777     Document Type: Article

References (41)

1. Mendelsohn, M.E. 2002. Protective effects of estrogen on the cardiovascular system. Am. J. Cardiol. 89:12E-17E.
2. Mendelsohn, M.E. 2000. Mechanisms of estrogen action in the cardiovascular system. J. Steroid Biochem. 74:337-343.
3. von Eckardstein, A., and Assmann, G. 2000. Prevention of coronary, heart disease by raising high-density lipoprotein cholesterol. Curr. Opin. Lipidol. 11:627-637.
4. Yuhanna, I.S., et al. 2001. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7:853-807.
5. Li, X.-A., et al. 2002. High-density lipoprotein binding to scavenger receptor class B, type I activates endothelial nitric oxide synthase in a ceramide-dependent manner. J. Biol. Chem. 277:11058-11063.
6. Hisamoto, K., et al. 2001. Estrogen induces the akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem. 276:3459-3467.
7. Chambliss, K.L., et al. 2000. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a function signaling module in caveolae. Circ. Res. 87:E44-E52.
8. Chambliss, K.L., Yuhanna, I.S., Anderson, R.G., Mendelsohn, M.E., and Shaul, P.W. 2002. ERβ has nongenomic action in caveolae. Mol. Endocrinol. 16:938-946.
9. Rubbo, H., Trostchansky, A., Botti, H., and Batthyany, C. 2002. Interactions of nitric oxide and peroxynitrite with low-density lipoprotein. Biol. Chem. 383:547-552.
10. Laroux, F.S., et al. 2000. Role of nitric oxide in the regulation of acute and chronic inflammation. Antioxid. Redox Signal. 2:391-396.
11. Lefer, A.M. 1997. Nitric oxide: nature's naturally occurring leukocyte inhibitor. Circulation. 95:553-554.
12. Li, H., and Forstermann, U. 2000. Nitric oxide in the pathogenesis of vascular disease. J. Pathol. 190:244-254.
13. Taddei, S., Virdis, A., Ghiadoni, L., Salvetti, G., and Salvetti, A. 2000. Endothelial dysfunction in hypertension. J. Nephrol. 13:205-210.
14. O'Connell, B.J., and Genest, J. 2001. High-density lipoproteins and endothelial function. Circulation. 16:1978-1983.
15. Libby, P. 2001. Managing the risk of atherosclerosis: the role of high-density, lipoprotein. Am. J. Cardiol. 20:3N-8N.
16. Tonkin, A. 2001. High-density lipoprotein cholesterol and treatment guidelines. Am. J. Cardiol. 20:41N-44N.
17. Bruce, C., Chouinard, R.A., and Tall, A.R. 1998. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu. Rev. Nutr. 18:297-330.
18. Sviridov, D., and Nestel, P. 2002. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 161:245-254.
19. Trigatti, B., Rigotti, A., and Krieger, M. 2000. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr. Opin. Lipidol. 11:123-131.
20. Krieger, M. 2001. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J. Clin. Invest. 108:793-797. doi:10.1172/JCI200114011.
21. Uittenbogaard, A., Shaul, P.W., Yuhanna, I.S., Blair, A., and Smart, E.J. 2000. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 275:11278-11283.
22. Matthews, K.A., Kuller, L.H., Sutton-Tyrrell, K., and Chang, Y.F. 2001. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke. 32:1104-1111.
23. Cid, M.C., Schnaper, H.W., and Kleinman, H.K. 2002. Estrogens and the vascular endothelium. Ann. N. Y. Acad. Sci. 966:143-157.
24. Langer, R.D. 2002. Hormone replacement and the prevention of cardiovascular disease. Am. J. Cardiol. 89:36E-46E.
25. Tolbert, T., and Oparil, S. 2001. Cardiovascular effects of estrogen. Am. J. Hypertens. 14:186S-193S.
26. Sader, M.A., and Celermajer, D.S. 2002. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc. Res. 53:597-604.
27. Chambliss, K.L., and Shaul, P.W. 2002. Rapid activation of endothelial NO synthase by estrogen: evidence for a steroid receptor fast-action complex (SRFC) in caveolae. Steroids. 67:413-419.
28. Wyckoff, M.H., et al. 2001. Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Gα(i). J. Biol Chem. 276:27071-27076.
29. Haynes, M.P., et al. 2000. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ. Res. 87:677-682.
30. Davda, R.K., Chandler, L.J., Crews, F.T., and Guzman, N.J. 1993. Ethanol enhances the endothelial nitric oxide synthase response to agonists. Hypertension. 21:939-943.
31. Schumaker, V.N., and Puppione, D.L. 1986. Sequential flotation ultracentrifugation. In Plasma lipoproteins. Part A: preparation, structure, and molecular biology. J.P. Segrest and J.J. Albers, editors. Academic Press, Inc. Orlando, Florida, USA. 155-170.
32. Gwynne, J.T., and Mahaffee, D.D. 1989. Rat adrenal uptake and metabolism of high density lipoprotein cholesteryl ester. J. Biol. Chem. 264:8141-8150.
33. Bilheimer, D.W., Eisenberg, S., and Levy, R.I. 1972. The metabolism of very low density lipoprotein. Biochim. Biophys. Acta 260:212-221.
34. Dubal, D.B., et al. 2001. Estrogen receptor α, not β, is a critical link in estradiol-mediated protection against brain injury. Proc. Natl. Acad. Sci. U. S. A. 98:1952-1957.
35. Gong, M.C., et al. 1992. Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle. J. Biol. Chem. 267:14662-14668.
36. Simoncini, T., et al. 2002. Genomic and nongenomic mechanisms of nitric oxide synthase induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology. 143:2052-2061.
37. Liu, B., and Krieger, M. 2002. Highly purified scavenger receptor class B, type I reconstituted into phosphatidylcholine/cholesterol liposomes mediates high affinity high density lipoprotein binding and selective lipid uptake. J. Biol. Chem. 277:34125-34135.
38. Kincer, J.F., et al. 2002. Hypercholesterolemia promotes a CD36-dependent and endothelial nitric oxide synthase-mediated vascular dysfunction. J. Biol. Chem. 277:23525-23533.
39. Smart, E.J., et al. 1999. Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell. Biol. 19:7289-7304.
40. Shaul, P.W. 2002. Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol. 64:749-774.
41. Grady, D., et al. 2002. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HEPS II), JAMA. 288:49-57.